

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report

New Delhi, India, 13–16 June 2017



REGIONAL OFFICE FOR

**World Health
Organization**
South-East Asia

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report

New Delhi, India, 13–16 June 2017

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization..

Suggested citation. South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acronyms	V
1. Introduction.....	1
2. Objectives	4
3. Conclusions and recommendations.....	5
3.1 RI system and services are strengthened (Goal 1).....	6
3.2 Measles is eliminated and rubella/CRS controlled (Goal 2)	10
3.3 Polio-free status is maintained (Goal 3).....	16
3.4 Elimination of maternal and neonatal tetanus is sustained (Goal 4) ...	21
3.5 Control of JE is accelerated (Goal 5)	22
3.6 Control of Hepatitis B is accelerated (Goal 6)	24
3.7 Introduction of new vaccine and related technologies is accelerated (Goal 7).....	27
3.8 Access to high quality vaccines is ensured (Goal 8).....	29

Annexes

1. Opening address by Regional Director	32
2. Agenda	36
3. List of participants.....	39

Acronyms

AD	auto-disable
AEFI	adverse event following immunization
AES	acute encephalitis syndrome
AFP	acute flaccid paralysis
bOPV	bivalent oral poliovirus vaccine
CAH	Child and Adolescent Health Programme
CCS	containment certification scheme
CDS	Communicable Diseases Department
cMYP	comprehensive multiyear plan
CRS	congenital rubella syndrome
DTP3	third dose of diphtheria-tetanus-pertussis vaccine
DHIS	district health information software
EAPRO	East Asia and Pacific Regional Office
EPI	Expanded Programme on Immunization
ES	environmental surveillance
GAPIII	WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use
Gavi	Gavi, the Vaccine Alliance
GDP	Good Distribution Practices
GHSSVH	Global Health Sector Strategy on Viral Hepatitis
GVAP	Global Vaccine Action Plan
HBV	chronic hepatitis B virus

HbsAg	hepatitis B surface antigen
HepB	hepatitis B vaccine
HepB3	third dose of hepatitis B vaccine
HepB-BD	hepatitis B vaccine birth dose
HPV	human papilloma virus
HSS	health system strengthening
ID	intra dermal
IEAG	India Expert Advisory Group
IPV	inactivated poliovirus vaccine
ITAG	Immunization Technical Advisory Group
IVD	Immunization and Vaccine Development Unit
JE	Japanese encephalitis
JICA	Japan International Cooperation Agency
JRF	Joint Reporting Form
LBs	live births
MeaNS	measles nucleotide surveillance
MCV	measles containing vaccine
MCV1	first dose of measles containing vaccine
MCV2	second dose of measles containing vaccine
MNCH	Maternal Neonatal Child Health Unit

预览已结束，完整报告

<https://www.yunbaogao.cn/report/inc>